Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ziftomenib (KO-539)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Kura Oncology, University of Michigan

Drug class:

Menin-MLL inhibitor

Related drugs:

‹

›

MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2	KO-539 Sensitive: C2 – Inclusion Criteria KO-539 Sensitive : C2
NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	NPM1 mutation + DNMT3A mutation + KMT2D mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
SETD2 mutation + RUNX1 mutation	Acute Myelogenous Leukemia	SETD2 mutation + RUNX1 mutation	Acute Myelogenous Leukemia	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3	KO-539 Sensitive: C3 – Early Trials KO-539 Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D	abemaciclib + KO-539 Sensitive: D – Preclinical abemaciclib + KO-539 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D	KO-539 + OTX015 Sensitive: D – Preclinical KO-539 + OTX015 Sensitive : D
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D
MLL mutation	Acute Myelogenous Leukemia	MLL mutation	Acute Myelogenous Leukemia	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D	venetoclax + KO-539 Sensitive: D – Preclinical venetoclax + KO-539 Sensitive : D
MLL rearrangement	Acute Myelogenous Leukemia	MLL rearrangement	Acute Myelogenous Leukemia	selinexor + KO-539 Sensitive: D – Preclinical selinexor + KO-539 Sensitive : D	selinexor + KO-539 Sensitive: D – Preclinical selinexor + KO-539 Sensitive : D